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Relationship between Chronic Kidney Disease and Risk of 
Coronary Heart Disease in Korean Men 
There have been many epidemiological researches of chronic kidney disease (CKD), 
accompanied by an increase in the incidence of coronary heart disease (CHD). However, as 
far as we know, little research has been done to examine the extent of the relationship 
between CKD and CHD as estimated by Framingham risk score (FRS) in Korean men. CKD 
was defined as either proteinuria or an eGFR of < 60 mL/min per 1.73 m
2. The FRS has 
been used to predict the 10-yr risk of coronary events and usually divided into three levels 
of risk < 10% (low), 10%-19% (intermediate) and ≥ 20% (high). We defined FRS ≥ 10% as 
more-than-a-moderate CHD risk group and FRS ≥ 20% as a high CHD risk group, 
respectively. After adjusting for covariates, multivariable-adjusted logistic regression 
analyses showed a strong statistical significant relationship between CKD and high risk of 
CHD (adjusted OR, 1.95 [95% CI, 1.32-2.87]). Dipstick urinalysis and eGFR can be readily 
measured in most clinical settings. The measurement of kidney function may represent a 
relatively inexpensive and efficient way to identify individuals at higher risk for CHD. 
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INTRODUCTION 
Chronic kidney disease (CKD) has been known to be associat-
ed with end stage renal disease (ESRD), as well as cardiovascu-
lar morbidity and mortality (1-3). CKD often progresses to ESRD 
with its attendant complications; treatment of the earlier stages 
of CKD is effective in slowing the progression towards ESRD (4, 
5). Recently, the number of patients with ESRD is increasing world-
wide (6, 7). According to data from the Third National Health 
and Nutrition Examination Survey, 8.3 million US adults aged 
20 yr or older have CKD (8). In 1999, the US Renal Data System 
documented that the number of long-term ESRD patients would 
increase up to 651,330 by 2010 (9). In Korea, there also has been 
a recent dramatic increase in the prevalence of patients with 
ESRD that require renal replacement therapy, from 303.6 per 
million population in 1994 to 1,113.6 per million population in 
2009 (10). CKD has been found to cause currently a worldwide 
public health problem (11); and thus, identification and man-
agement of the modifiable risk factors for CKD are important 
for preventing adverse effects and improving patient outcome. 
  Coronary heart disease (CHD) proves to be the major cause 
of mortality and morbidity worldwide, estimating CHD risk in 
clinical settings is of critical importance for primary and second-
ary prevention strategies. Most of the well-recognized risk fac-
tors of CHD have been considered in the development of the 
Framingham risk score (FRS). The FRS is recognized as an im-
portant clinical tool to indicate the intensity of CHD risks and 
guide the appropriate interventions for risks (12). It is well estab-
lished that CKD is a single most important risk factor to cardio-
vascular events. 
  In fact, Go et al. (1) reported that among the American popu-
lation patients with mild CKD already showed substantial in-
creases in the frequency of cardiovascular events. There have 
been many epidemic researches of CKD across the world, ac-
companied by an increase in the incidence of CHD (13-15). How-
ever, as far as we know, little research has been done to exam-
ine the extent of the relationship between CKD and CHD as es-
timated by FRS in Korean men. The aim of this study was to de-
termine the relationship between severity of CKD and FRS in 
Korean men, which are well known markers for 10-yr risk of 
CHD incidence.
MATERIALS AND METHODS 
Study design 
A cross-sectional study was conducted to examine the associa-
tion between CKD and the risk of CHD in Korean men who were 
employed at various companies in Korea. All employees partic-
ipate in an annual health check-up, as is required by Korea’s In-
dustrial Safety and Health law. A total of 55,260 men who had 
visited the Kangbuk Samsung Hospital, Healthcare Center for a 
medical check-up from January to December in 2008 participat-
ed in this study. Study data included laboratory, physical exam-
ination and information provided by a questionnaire.Ryoo J-H, et al.  •  Chronic Kidney Disease and Coronary Heart Disease
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Study population 
Among the 55,260 subjects, 2,039 were excluded by various rea-
sons: 1,853 from our study subjects were not calculating FRS; 
69 were not assessing serum creatinine; 117 were not possess-
ing information about proteinuria. Ultimately, 53,221 men, aged 
21 to 77 yr old, were enrolled in the analysis and were observed 
the relationship between CKD and the risk of CHD estimated 
by FRS. 
Clinical and laboratory measurements 
Study data included a medical history, a physical examination, 
information provided by a questionnaire, anthropometric mea-
surements and laboratory measurements. The medical history 
and the history of drug prescription were assessed by the exam-
ining physicians. All the participants were asked to respond to a 
questionnaire on health-related behavior. Questions about al-
cohol intake included the frequency of alcohol consumption 
on a weekly basis and the usual amount that was consumed on 
a daily basis (≥ 20 g/day). We considered persons reporting that 
they smoked at that time to be current smokers. Blood samples 
were collected after more than 12 hr of fasting and were drawn 
from an antecubital vein. The fasting serum glucose, total cho-
lesterol, triglycerides, low-density lipoprotein (LDL) cholester-
ol, high-density lipoprotein (HDL) cholesterol and blood urea 
nitrogen (BUN) were measured enzymatically with an automat-
ic analyzer (Advia 1650 Autoanalyzer, Bayer Diagnostics; Lever-
kusen, Germany). The fasting serum glucose was measured with 
the hexokinase method. Total cholesterol and serum triglycer-
ide were measured with enzymatic colorimetric tests, LDL-cho-
lesterol was measured with the homogeneous enzymatic colo-
rimetric test, and HDL-cholesterol was measured with the selec-
tive inhibition method (Bayer Diagnostics). Insulin levels were 
measured with immunoradiometric assays (Biosource, Belgium). 
Insulin resistance was calculated with the Homeostasis Model 
Assessment of insulin resistance (HOMA-IR): fasting serum in-
sulin (μU/mL) × fasting blood glucose (mg/dL)/22.5. The serum 
creatinine was measured with the alkaline picrate (Jaffe) meth-
od. The urine protein level was determined at each examina-
tion from the results of a single urine dipstick semiquantitative 
analysis (URiSCAN
® Urine strip, YD Diagnostics; Korea). Dip-
stick urinalysis was performed on fresh, midstream urine sam-
ples that were collected in the morning. The results of the urine 
test were based on a scale that quantified proteinuria as absent, 
trace, 1+, 2+, 3+, and 4+. The dipstick results of 1+, 2+, 3+, and 
4+ corresponded to protein levels of approximately 30, 100, 300, 
and 1,000 mg/dL, respectively. Kidney function was estimated 
by the glomerular filtration rate (GFR), which was calculated 
with the simplified Modification of Diet in Renal Disease Study 
equation that is defined as estimated glomerular filtration rate 
(eGFR) = 186.3 × (serum creatinine)
-1.154 × age
-0.203 (16, 17). Pro-
teinuria was defined as a finding of 1+ or greater. CKD was de-
fined as either proteinuria or an eGFR of < 60 mL/min per 1.73 
m
2. Trained nurses obtained sitting blood pressure levels with a 
standard mercury sphygmomanometer. The first and fifth Korot-
koff sounds were utilized in order to estimate the systolic blood 
pressure and the diastolic blood pressure. Height and weight 
were measured after an overnight fast with the subjects wearing 
a lightweight hospital gown and no shoes. The BMI was calcu-
lated as the weight (kg) divided by the square of the height (m). 
Framingham risk score 
The FRS was calculated from the National Cholesterol Educa-
tion Program (NCEP) Adult Treatment Panel (ATP) III algorithm, 
based on six coronary risk factors: gender, age, total cholesterol, 
HDL-cholesterol, systolic BP and smoking habit (12). Among 
these factors, age, BP, and cholesterol levels were categorized 
according to their values and smoking status was classified as 
either “current smoker” or “non-smoker” . Finally, the correspond-
ing point was given to each man and then the total score was 
used as the individual’s CHD risk level. The FRS has been used to 
predict the 10-yr risk of coronary events (fatal/nonfatal myocar-
dial infarction, coronary-associated mortality or sudden death) 
(18), and usually divided into three levels of risk < 10% (low), 10%-
19% (intermediate) and ≥ 20% (high) (12, 18). In this study, we 
defined FRS ≥ 10% as more-than-a-moderate CHD risk group 
and FRS ≥ 20% as a high CHD risk group, respectively. 
Statistical analyses
Initially, we compared the characteristics of participants in re-
lation to the proportion of the dipstick urinalysis, eGFR stages 
and CKD. The one-way ANOVA and chi-square test were used 
to analyze the statistical differences across the characteristics of 
the study participants in relation to 10 yr-predicted-risk groups 
of the FRS. All multiple comparisons were conducted with the 
tukey method. More-than-a-moderate risk (FRS ≥ 10%) and 
high risk (FRS ≥ 20%) were considered as dependent variables. 
The logistic regression analyses were conducted to calculate the 
odds ratio (OR) and 95% confidence interval (CI). The data were 
first unadjusted, then adjusted for the multiple covariates. In 
multivariable model, age, HOMA-IR, BMI, hypertensive medi-
cation, diabetic medication and alcohol intake were included 
for adjustment. The statistical analysis for the data was performed 
with SPSS version 17.0 (SPSS Inc.). All the reported P values were 
two-tailed, and those < 0.05 were considered to be statistically 
significant.
Ethics statement 
This study was approved by the institutional review board of the 
Kangbuk Samsung Hospital, Sungkyunkwan University, School 
of Medicine in Seoul, Korea (IRB number: KBC10069). All par-
ticipants gave their written informed consent.Ryoo J-H, et al.  •  Chronic Kidney Disease and Coronary Heart Disease
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RESULTS
Overall, the mean age and eGFR were 43.7 ± 8.3 yr and 80.5 ± 9.9 
mL/min per 1.73 m
2, respectively (data mean ± S.D.). The over-
all prevalence of CKD was 4.2% (data not shown). Anthropomet-
ric, clinical, and laboratory data of those in relation to the pro-
portion of the dipstick urinalysis, eGFR stages and CKD were 
shown in Table 1.
  The risk factors found to be significantly associated with CKD 
were as follows: age, BMI, systolic and diastolic BP, total choles-
terol, triglyceride, LDL-cholesterol, fasting serum glucose, HOMA-
IR, insulin level, BUN, FRS and alcohol intake. The clinical char-
acteristics of the study participants in relation to 10 yr-predict-
ed-risk groups of the FRS were shown in Table 2. All clinical vari-
ables showed statistical significance. In the categorical analy-
ses, the risk for CKD significantly increased with 10 yr-predict-
ed-risk groups of the FRS. Table 3 presented the OR and 95% CI 
of the risk of CHD. 
  After adjusting for age, HOMA-IR, BMI, hypertensive medi-
cation, diabetic medication and alcohol intake, multivariable-
adjusted logistic regression analyses showed a strong statistical 
significant relationship between CKD and high risk of CHD (ad-
justed OR, 1.95 [95% CI, 1.32-2.87]). In unadjusted analyses, the 
OR of eGFR < 60 was bigger than that of proteinuria in both more-
than-a-moderate risk and high risk group of CHD. After adjust-
ing for confounding variables, the OR of proteinuria only re-
mained statistically significant.  
 
DISCUSSION
The aim of this study was to determine whether individuals with 
CKD have an elevated 10-yr risk of CHD estimated by FRS. By 
Table 1. Comparison of baseline characteristics of proteinuria, eGFR and CKD (N = 53,221)
Variables
Dipstick urinalysis (N = 53,221) eGFR (N = 53,221) CKD (N = 53,221)
0  
(n = 51,640)
+1  
(n = 1,038)
≥ +2  
(n = 543)
P 
value*
≥ 60  
(n = 52,493)
< 60, > 55 
(n = 536)
≤ 55  
(n = 192)
P 
value
†
CKD  
(n = 2,248)
Non-CKD  
(n = 50,973)
P 
value
‡
Age (yr) 43.6 ± 
8.2
45.4 ± 
9.7
46.2 ± 
9.7
< 0.001 43.5 ± 
8.2
53.2 ± 
10.0
56.5 ± 
10.7
< 0.001 48.2 ± 
10.6
43.5 ± 
8.1
< 0.001
BMI (kg/m
2)  24.5 ± 
2.8
24.7 ± 
3.1
25.2 ± 
3.3
< 0.001 24.5 ± 
2.8
25.3 ± 
2.6
25.2 ± 
2.7
< 0.001 25.0 ± 
3.0
24.5 ± 
2.8
< 0.001
Systolic BP (mmHg)  118.1 ± 
12.6
120.2 ± 
14.6
124.3 ± 
16.4
< 0.001 118.2 ± 
12.6
123.0 ± 
14.3
122.1± 
13.8
< 0.001 121.9 ± 
15.0
118.0 ± 
12.5
< 0.001
Diastolic BP (mmHg)  76.9 ± 
8.7
79.1 ± 
9.2
81.4 ± 
10.4
< 0.001 77.0 ± 
8.7
79.9 ± 
8.8
78.8 ± 
9.0
< 0.001 79.8 ± 
9.4
76.9 ± 
8.7
< 0.001
Total cholesterol  
   (mg/dL) 
199.1 ± 
33.0
205.5 ± 
37.0
206.5 ± 
37.8
< 0.001 199.3 ± 
33.1
205.7 ± 
33.4
202.3 ± 
36.1
< 0.001 205.5 ± 
36.7
199.1 ± 
32.9
< 0.001
Triglyceride (mg/dL)  149.4 ± 
93.9
159.9 ± 
108.8
191.6 ± 
174.3
< 0.001 149.8 ± 
95.5
165.0 ± 
101.3
157.2 ± 
87.6
< 0.001 167.6 ± 
124.5
149.3 ± 
93.9
< 0.001
HDL-cholesterol  
   (mg/dL) 
51.5 ± 
10.9
51.7 ± 
11.6
51.7 ± 
11.5
0.641 51.5 ± 
10.9
50.4 ± 
11.0
50.3 ± 
11.7
0.018 51.4 ± 
11.5
51.5 ± 
10.9
0.634
LDL-cholesterol  
   (mg/dL) 
115.8 ± 
28.7
120.0 ± 
31.6
117.3 ± 
32.9
< 0.001 115.8 ± 
28.8
118.8 ± 
30.8
116.5 ± 
30.6
0.064 118.9 ± 
31.7
115.7 ± 
28.7
< 0.001
Fasting serum  
   glucose (mg/dL)
97.7 ± 
16.1
103.1 ± 
29.7
112.6 ± 
42.1
< 0.001 97.9 ± 
17.0
100.4 ± 
18.4
105.2 ± 
25.1
< 0.001 104.6 ± 
30.8
97.6 ± 
16.1
< 0.001
HOMA-IR  1.5 ± 
1.1
1.7 ± 
1.2
3.3 ± 
3.8
< 0.001 1.5 ± 
1.1
1.9 ± 
1.3
2.8 ± 
5.5
< 0.001 2.2 ± 
2.3
1.5 ± 
1.1
< 0.001
Insulin (µU/dL)  6.2 ± 
3.8
6.5 ± 
4.1
9.9 ± 
9.5
< 0.001 6.2 ± 
3.8
7.3 ± 
4.3
9.0 ± 
14.5
< 0.001 7.6 ± 
6.2
6.2 ± 
3.8
< 0.001
eGFR (mL/min per  
   1.73 m
2)  
80.6 ± 
9.9
78.4 ± 
10.2
76.6 ± 
11.7
< 0.001 80.8 ± 
9.6
58.0 ± 
1.3
52.0 ± 
2.4
< 0.001 71.5 ± 
13.3
80.9 ± 
9.5
< 0.001
Creatinine (mg/dL)  1.0 ± 
0.1
1.1 ± 
0.1
1.1 ± 
0.1
< 0.001 1.1 ± 
0.1
1.4 ± 
0.1
1.5 ± 
0.1
< 0.001 1.2 ± 
0.2
1.1 ± 
0.1
< 0.001
BUN (mg/dL)  14.4 ± 
3.2
15.3 ± 
3.7
15.6 ± 
3.6
< 0.001 14.4 ± 
3.2
17.3 ± 
3.6
19.3 ± 
4.3
< 0.001 16.1 ± 
3.9
14.3 ± 
3.2
< 0.001
FRS  7.0 ± 
5.2
8.4 ± 
5.1
9.0 ± 
4.8
< 0.001 7.0 ± 
5.2
10.7 ± 
3.4
10.9 ± 
3.5
< 0.001 9.3 ± 
4.7
6.9 ± 
5.2
< 0.001
Current smoker, n (%) 20,654 
(40.0)
510  
(49.1)
253  
(46.6)
< 0.001 21,220 
(40.4)
161  
(30.0)
36  
(18.8)
< 0.001 941  
(41.9)
20,476 
(40.2)
0.110
Alcohol intake, n (%) 9,238 
(17.9)
256  
(24.8)
151  
(27.9)
< 0.001 9,517 
(18.2)
100  
(18.7)
28  
(14.6)
0.431 523  
(23.3)
9,122 
(17.9)
< 0.001
All values are the mean ± SD or the number of subjects (percent of the total). The dipstick urinalysis of trace was regarded as absent. *P value by ANOVA-test for continuous 
variables and Chi square test for categorical variables among dipstick urinalysis categories; 
†P value by ANOVA-test for continuous variables and Chi square test for categorical 
variables among eGFR categories; 
‡P value by t-test for continuous variables and Chi square test for categorical variables between CKD and non-CKD. BMI, body mass index; 
BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HOMA-IR, Homeostasis Model Assessment of insulin resistance; eGFR, estimated glomerular 
filtration rate; BUN, blood urea nitrogen; FRS, Framingham risk score.Ryoo J-H, et al.  •  Chronic Kidney Disease and Coronary Heart Disease
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multivariate logistic regression analysis, after adjusting for age, 
HOMA-IR, BMI, hypertensive medication, diabetic medication, 
and alcohol intake, CKD was found to be independently related 
to CHD. The results of our study identified that CKD was inde-
pendently associated with an elevated CHD risk in Korean men, 
regardless of known coronary risk factors such as age, HOMA-
IR, BMI, hypertension, diabetes mellitus and alcohol intake. 
  FRS provides estimates of total CHD events (defined as angi-
na pectoris, myocardial infarction and coronary-associated mor-
tality). Thus, a higher FRS reflects a greater 10-yr risk of develop-
ing CHD. FRS is transformed using the Framingham equation 
to 10-yr CHD risk estimates, that is, low risk < 10%, 10% ≤ mod-
erate risk < 20% and high risk ≥ 20%. In this study, we defined 
FRS ≥ 10% as more-than-a-moderate CHD risk group and FRS 
≥ 20% as a high CHD risk group. The FRS was used as a depen-
Table 2. Characteristics of the study subjects stratified for 10-yr predicted risk groups (N = 53,221)
Variables
10 -yr Predicted Risk Groups of FRS  P 
for trend* Multiple comparison
Low (n = 41,907) Intermediate (n = 9,405) High (n = 1,909)
Age (yr)  41.8 ± 6.8 50.3 ± 9.3   52.9 ± 10.0 < 0.001 1st ≠ 2nd, 1st ≠3rd, 2nd≠3rd
BMI (kg/m
2)  24.4 ± 2.8 25.1 ± 2.8 25.8 ± 2.9 < 0.001 1st ≠ 2nd, 1st ≠3rd, 2nd≠3rd
Systolic BP (mmHg)  117.1 ± 11.9 121.1 ± 13.9 128.1 ± 15.3 < 0.001 1st ≠ 2nd, 1st ≠3rd, 2nd≠3rd
Diastolic BP (mmHg)  76.4 ± 8.5 78.8 ± 9.1 81.9 ± 9.8 < 0.001 1st ≠ 2nd, 1st ≠3rd, 2nd≠3rd
Total cholesterol (mg/dL)  194.9 ± 31.4 213.0 ± 31.8 230.2 ± 41.0 < 0.001 1st ≠ 2nd, 1st ≠3rd, 2nd≠3rd
Triglyceride (mg/dL)  138.9 ± 82.0   180.7 ± 108.5   243.0 ± 180.4 < 0.001 1st ≠ 2nd, 1st ≠3rd, 2nd≠3rd
HDL-cholesterol (mg/dL)    52.4 ± 11.0   49.0 ± 10.1 44.3 ± 7.8 < 0.001 1st ≠ 2nd, 1st ≠3rd, 2nd≠3rd
LDL-cholesterol (mg/dL)  112.3 ± 27.4 127.3 ± 28.6 137.4 ± 36.3 < 0.001 1st ≠ 2nd, 1st ≠3rd, 2nd≠3rd
Fasting serum glucose (mg/dL)    96.8 ± 14.7 101.4 ± 22.2 106.1 ± 27.2 < 0.001 1st ≠ 2nd, 1st ≠3rd, 2nd≠3rd
HOMA-IR   1.5 ± 1.0   1.8 ± 1.4   2.1 ± 1.6 < 0.001 1st ≠ 2nd, 1st ≠3rd, 2nd≠3rd
Insulin (µU/dL)    6.1 ± 3.7   6.9 ± 4.5   8.1 ± 4.9 < 0.001 1st ≠ 2nd, 1st ≠3rd, 2nd≠3rd
eGFR (mL/min per 1.73m
2)  81.2 ± 9.8 78.2 ± 9.9   77.1 ± 10.7 < 0.001 1st ≠ 2nd, 1st ≠3rd, 2nd≠3rd
Creatinine (mg/dL)    1.08 ± 0.10   1.08 ± 0.12   1.09 ± 0.12 0.001 1st ≠3rd
BUN (mg/dL)  14.3 ± 3.2 14.9 ± 3.5 15.1 ± 3.5 < 0.001 1st ≠ 2nd, 1st ≠3rd
Current smoker, n (%) 12,709 (30.3) 7,053 (75.0) 1,655 (86.7) < 0.001
Alcohol intake, n (%)   6,718 (16.0) 2,428 (25.9)    499 (26.2) < 0.001
Proteinuria, n (%) 1,070 (2.5)  382 (4.1)  129 (6.8) < 0.001
eGFR < 60, n (%)    367 (0.9)  274 (2.9)    87 (4.6) < 0.001
Chronic kidney disease, n (%) 1,408 (3.4)  630 (6.7)    210 (11.0) < 0.001
All values are the mean ± SD or the number of subjects (percent of the total). *P value by ANOVA-test for continuous variables and Chi square test for categorical variables. 
BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HOMA-IR, Homeostasis Model Assessment of insulin resistance; eGFR, 
estimated glomerular filtration rate; BUN, blood urea nitrogen.
Table 3. Odds ratio and 95% confidence intervals assessing the independent influence of CKD on more-than-a-moderate risk (FRS ≥ 10%) and high risk (FRS ≥ 20%) of CHD 
Variables 
FRS ≥ 10% (vs < 10%) FRS ≥ 20% (vs < 20%)
Unadjusted Multivariate-adjusted* Unadjusted Multivariate-adjusted*
CKD (vs Non-CKD)  2.31 (2.11-2.52) 1.27 (0.96-1.68) 2.99 (2.57-3.47) 1.95 (1.32-2.87)
   Proteinuria (vs Non- Proteinuria)
   eGFR < 60 (vs eGFR ≥ 60)
1.81 (1.62-2.01)
3.73 (3.22-4.32)
1.61 (1.15-2.25)
0.86 (0.54-1.36)
2.49 (2.07-3.00)
3.78 (3.00-4.75)
2.97 (1.87-4.70)
0.93 (0.50-1.72)
Age 1.15 (1.14-1.15) 1.11 (1.11-1.12)
HOMA-IR 1.28 (1.24-1.32) 1.32 (1.25-1.38)
BMI 1.11 (1.10-1.11) 1.16 (1.14-1.18)
Hypertensive medication   3.48 (3.30-3.68) 5.18 (4.71-5.71)
Diabetic medication   2.90 (2.66-3.17) 3.29 (2.84-3.82)
Alcohol intake 1.83 (1.74-1.93) 1.63 (1.47-1.81)
*Multivariate-adjusted for age, HOMA-IR, BMI, hypertensive medication, diabetic medication and alcohol intake. CKD, chronic kidney disease; FRS, Framingham risk score; 
CHD, coronary heart disease; HOMA-IR, Homeostasis Model Assessment of insulin resistance; BMI, body mass index.
dent variable, and it is the first study that using FRS as depen-
dent variable instead of CHD events or mortality.
  Although the exact mechanisms by which CKD relates to CHD 
remain unclear, it is possible that renal dysfunction may have 
led to CHD. Subtle decrements in kidney function may activate 
the renin-angiotensin-aldosterone system and the sympathetic 
nervous system. Upregulation of the renin-angiotensin-aldo-
sterone system may lead to CHD by promoting Inflammatory 
process including atherosclerosis, nephropathy and cardiomy-
opathy (19, 20). 
  This study had some limitations, despite being conducted on 
a large representative sample of the general population. First, 
FRS should be applied to individuals who are over 30 yr old (21), 
but in this study, study participants were ≥ 20 yr old and FRS 
may less accurately predict the risk of CHD in younger individ-Ryoo J-H, et al.  •  Chronic Kidney Disease and Coronary Heart Disease
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uals. The number of study participants aged between 20 and 29 
was only 378, which occupied 0.71%. Thus, that could not cause 
bias. Second, this study was just confined to relatively racially 
homogeneous male of individuals of Korean ancestry who were 
recruited at a single urban hospital, which introduced the pos-
sibility of bias. Additionally, the participants were self-selected, 
so this study might show participant selection bias. Some stud-
ies have shown that ethnicity affects the presence and severity 
of CHD independently of atherosclerotic risk factors (22, 23). In 
fact, the original Framingham equations overestimated the risk 
of 5-yr CHD events in Chinese, Japanese American and Hispan-
ic men and Native American women, and thus, specific popu-
lation risk equations are required to take into account different 
prevalence of risk factors and underlying rates of developing 
CHD (24, 25). It may also overestimate in Koreans with signifi-
cant different genetic and environmental backgrounds. How-
ever, in this study, FRS was used as a risk stratification tool, not 
for calculating absolute risks of CHD among racially different 
groups. Third, we used an eGFR instead of a directly measured 
GFR to define CKD. A recent review article reported that current 
eGFR had a greater inaccuracy in populations without known 
CKD than in those with the disease (26). Nonetheless, current 
eGFR facilitates the detection, evaluation, and management of 
CKD, and many organizations recommend the use of equations 
that estimate GFR in epidemiologic studies and in clinical prac-
tice for the evaluation of renal function (26). Therefore, our find-
ings were applicable to clinical and public health practice set-
tings. Regardless of these limitations, strength of the present 
study is that the number of relatively healthy male participants 
is large enough to show the evidence for correlations between 
CKD and CHD. 
  In conclusion, as far as we know, this is the first study to ex-
plore the relation between CKD and CHD, as determined using 
FRS in a large population. Those with CKD were found to have 
an elevated 10-yr risk of CHD. Furthermore, CKD was found to 
be independently related to CHD regardless of classical athero-
sclerotic risk factors. These findings highlight the importance of 
regular surveillance and monitoring of renal function for pre-
vention of CHD (27). Mild to moderate kidney dysfunction is 
highly prevalent. Dipstick urinalysis and eGFR can be readily 
measured in most clinical settings. If kidney dysfunction pre-
cedes the onset of CHD, the measurement of kidney function 
may represent a relatively inexpensive and efficient way to iden-
tify individuals at higher risk for CHD. 
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AUTHOR SUMMARY
Relationship between Chronic Kidney Disease and Risk of Coronary Heart Disease 
in Korean Men 
Jae-Hong Ryoo, Soo-Geun Kim, Byung-Seong Suh, Dong-Il Kim and Sung Keun Park
Chronic kidney disease (CKD) has been known to be associated with end stage renal disease (ESRD). It is well established that CKD 
is a single most important risk factor to coronary heart disease (CHD). Estimating CHD risk in clinical settings is of critical 
importance for prevention. Most of the well-recognized risk factors of CHD have been considered in the development of the 
Framingham risk score (FRS). The aim of this study is to determine the relationship between severity of CKD and FRS in Korean 
men. Multivariable-adjusted logistic regression analyses showed a strong statistical significant relationship between CKD and high 
risk of CHD (adjusted OR, 1.95 [95% CI, 1.32-2.87]). Dipstick urinalysis and eGFR can be readily measured in clinical settings. 
These findings highlight the importance of regular surveillance and monitoring of renal function for prevention of CHD. 